durvalumab,sorafenib,tremelimumab
astrazeneca,pfizer
['hcc']
 discussant #asco23 are imaes early markers of response to stride? but rightfully need data on cost-effectiveness and highlights the prognostic implications of qol metrics on os in #hcc and #cholangiocarcinoma among other imp reasons to look at these 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope